Skip to search formSkip to main contentSkip to account menu

deramciclane

Known as: 2-phenyl-2-(dimethylaminoethoxy)-1,7,7-trimethylbicyclo(2.2.1)heptane hemifumarate, N,N-dimethyl-2-((1,7,7-trimethyl-2-phenylbicyclo(2.2.1)hept-2-yl)oxy)ethamine 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The metabolic fate of deramciclane [(1R,2S,4R)-(–)-2-phenyl-2-(2′-dimethylamino-ethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane], a… 
2003
2003
BackgroundIn vitro findings have indicated that the novel anxiolytic drug, deramciclane, is an inhibitor of the cytochrome P450… 
2003
2003
RationalePreliminary in vitro findings indicated that the novel anxiolytic drug, deramciclane is a substrate for the cytochrome… 
2001
2001
Abstract. Objective: To investigate whether a 5-hydroxytryptamine (5-HT) reuptake inhibitor (paroxetine) has an anxiogenic-like… 
2000
2000
The pharmacokinetic properties of deramciclane fumarate (EGIS‐3886), a new potential anxiolitic agent, and its N‐desmethyl… 
1999
1999
The pharmacokinetics and tolerability of a new putative non‐benzodiazepine type anxiolytic compound deramciclane was studied in… 
1999
1999
Abstract The influence of serotonergic and benzodiazepine type anxiolytic drugs on the cortical activation and sleep-wakefulness… 
1998
1998
Abstract Deramciclane (EGIS-3886) is a novel anxiolytic agent that binds with high affinity to 5-HT2A/2C receptors. The… 
Highly Cited
1998
Highly Cited
1998
Abstract The activity of anxiolytic and other drugs in a light-dark test situation was studied in rats treated with the… 
1998
1998
We have studied the dog model for predicting the oral absorption of deramciclane, a novel anxiolytic compound, as a model acid…